Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A known ✓ | P46098 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 4/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | TACR2 | P21452 | 1/20 | 0.50 |
| ▸ | TACR1 | P25103 | 1/20 | 0.50 |
| ▸ | HRH1 | P35367 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9695580 | 0.99 | POLB (0.60) | POLBKDM4EHTR3ATACR2TACR1 | |
| Hydrochloric Acid SCHEMBL7887857 | 0.87 | HTR3A (0.52) | POLBKDM4EHTR3ATACR2TACR1 | |
| Bromide SCHEMBL9695606 | 0.86 | POLB (0.62) | POLBKDM4ETACR2TACR1HRH1 | |
| SCHEMBL9260920 | 0.85 | KDM4E (0.50) | KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL7954906 | 0.81 | HRH1 (0.52) | KDM4EHRH1ALDH1A1 | |
| Fumaric Acid SCHEMBL9697232 | 0.81 | POLB (0.58) | POLBKDM4ETACR2TACR1HRH1 | |
| SCHEMBL9262955 | 0.81 | HSD17B10 (0.44) | POLBKDM4ETACR2TACR1HRH1 | |
| SCHEMBL7468259 | 0.81 | HTR3A (0.54) | POLBKDM4EHTR3AALDH1A1TP53 | |
| SCHEMBL7474308 | 0.80 | HRH1 (0.62) | HTR3ATACR2TACR1HRH1TP53 | |
| SCHEMBL7471446 | 0.79 | HRH1 (0.42) | POLBKDM4ETACR2TACR1HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7732437-B2 | Use of anti-histaminics for acute reduction of elevated intracranial pressure | JANSSEN PHARMACEUTICA, NV. (BE) | 2010-06-08 | — | — | US | disclosed |
| US-20050070525-A1 | Use of anti-histaminics for acute reduction of elevated intracranial pressure | JANSSEN-CILAG GMBH (DE) | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070525-A1 | Use of anti-histaminics for acute reduction of elevated intracranial pressure | HRH2, HRH3, HRH4 | HTR3A 75/4885POLB 3028/4885KDM4E 3457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.